• Portfolio
  • Latest Articles

CLINICAL STUDIES

March 9th

NTI secures strategic Cultivation partnership to grow and maintain its medical cannabis

  Archived
Neurotech expands exclusive license to include all neurological disorders

March 2nd 2021

Neurotech expands exclusive license to include all neurological disorders

Neurotech to commence clinical study program this quarter

February 15th 2021

Neurotech to commence clinical study program this quarter

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await

December 21st 2020

NTI Complete In Vitro Studies on Cannabis Strains, Clinical Trials Await

OncoSilâ„¢ receives CE Mark approval

April 1st 2020

OncoSilâ„¢ receives CE Mark approval

Connect with us

EXPLORE

  • Finfeed Portfolio
  • Latest Articles
  • How It Works
  • Archived Articles
  • About StocksDigital
  • News
  • PORTFOLIOS

  • Next Investors
  • Catalyst Hunter
  • Wise-Owl
  • STOCKS

    FOLLOW OUR INVESTMENT COMMENTARY & ANALYSIS
      CUSTOMER NOTICE | PRIVACY POLICY | FINANCIAL SERVICES GUIDE | DISCLOSURE POLICY  
    The information in this website is general information only. Any advice is general advice only. Your personal objectives, financial situation or needs have not been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice. S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877).
    © 2021   |   AFSL (CAR No.433913)